18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Clinical trial NCT03732352 · COMPLETED

Trial details

NCT number: NCT03732352
Sponsor: Jonsson Comprehensive Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Gene Amplification EGFR Gene Mutation Glioblastoma Recurrent Glioblastoma Supratentorial Glioblastoma TP53 Wt Allele

Start date: 2018-11-28
Primary completion: 2024-01-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.